PharmaNet Development Group, Inc. to Present at the Wachovia Small and Mid-Cap Healthcare Conference on Tuesday, January 30, 200
09 January 2007 - 10:50PM
Business Wire
PharmaNet Development Group, Inc. (NASDAQ: PDGI) today announced
that Jeffrey P. McMullen, president and chief executive officer,
will make a presentation on the Company at the Wachovia Small and
Mid-Cap Healthcare Conference on Tuesday, January 30, 2007 at 3:30
PM EST. The conference will take place at the Langham Hotel,
Boston, Massachusetts. A live audio webcast of the presentation
will be accessible from the investor tab of PharmaNet�s web site at
www.pharmanet.com. The replay of the webcast will be available
within approximately one hour of the live presentation and will
remain available for approximately 60 days following the
conference. About PharmaNet Development Group, Inc. PharmaNet
Development Group, Inc. is an international drug development
services company offering a comprehensive range of clinical
development, clinical and bioanalytical laboratory, and consulting
services to the branded pharmaceutical, biotechnology, generic drug
and medical device industries. PharmaNet Development Group, Inc.
has more than 30 offices, facilities and laboratories with more
than 2,000 employees strategically located throughout the world.
For more information, visit the Company's Web site at
http://www.pharmanet.com. Forward-Looking Statements Certain
statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include, but are not limited to,
industry trends and information; whether adverse publicity relating
to the Company�s discontinued Florida operations causes clients to
select competitors, not only for early stage branded clinical
trials but also for other aspects of the Company�s business; its
ability to comply with the timeline agreed upon in the settlement
reached with the Miami-Dade County Unsafe Structures Board and any
related fines or expenses if we are unsuccessful complying with
such timeline; the associated costs and expenses with discontinuing
the Company's operations in Florida, including the potential costs
of the demolition of the Miami facility; the Company's ability to
determine its impairment charges and costs of discontinued
operations; whether the Company will achieve its estimated value
for its Miami property; developments with respect to the SEC's
inquiry and securities class action lawsuits and derivative
lawsuits; the Company�s ability to successfully achieve and manage
the technical requirements of specialized clinical trial services,
while complying with applicable rules and regulations; regulatory
changes; changes affecting the clinical research industry; a
reduction of outsourcing by pharmaceutical and biotechnology
companies; the Company�s ability to compete internationally in
attracting clients in order to develop additional business; the
Company�s evaluation of its backlog and the potential cancellation
of contracts; its ability to retain and recruit new employees; its
clients' ability to provide the drugs and medical devices used in
its clinical trials; the Company�s future stock price; its
assessment of its effective tax rate; the Company�s financial
guidance; the future effective tax rate; our anticipated capital
expenditures; our costs of compliance of Section 404 of the
Sarbanes-Oxley Act; our ability to remediate our material
weaknesses; the impact of foreign currency transaction costs and
the effectiveness of any hedging strategies that we implement; and
the national and international economic climate as it affects drug
development operations. Further information can be found in the
Company�s risk factors contained in its Annual Report on Form 10-K
for the year ended December 31, 2005, which were originally filed
as SFBC International (NASDAQ: SFCC) and its most recent Quarterly
Report on Form 10-Q. The Company does not undertake to update the
disclosures made herein, and you are urged to read our filings with
the Securities and Exchange Commission.
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Pharmanet Development Grp (MM) (NASDAQ:PDGI)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Pharmanet Development Grp (MM) (NASDAQ): 0 recent articles
More PharmaNet Development Group, Inc. News Articles